This article is more than 5 years old. Information may no longer be current.

FDA approves two higher dosage strengths of Zubsolv for opioid dependence

The FDA has approved two higher dosages of buprenorphine/naloxone sublingual tablets for the maintenance treatment of opioid dependence, according to an Orexo press release.

The new 8.6-mg/2.1-mg dosage of buprenorphine/naloxone (Zubsolv, Orexo) CIII sublingual tablet is expected to launch early 2015; the 11.4 mg/2.9 mg later in 2015.

Existing tablets are available in 5.7-mg/1.4-mg and 1.4-mg/0.36-mg dosages.

The new formulations possess improved taste and faster dissolve time, according to the release.